Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta-lactamase inhibitors]

O Launay1, M L Joly-Guillou, D Decré

  • 1Service de Médicine interne, Hôpital Bichat-Claude Bernard, Paris.

Presse Medicale (Paris, France : 1983)
|March 29, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of latent TB infection: a national survey of French physicians.

IJTLD open·2025
Same author

Influenza and pneumococcal vaccine coverage among adults hospitalized with acute respiratory infection in France: A prospective cohort study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2025
Same author

Cost-effectiveness and public health impact of using high dose quadrivalent influenza vaccine in the French older adults population.

Journal of medical economics·2024
Same author

Effect of achieving bone sterilisation on bone architecture and bone marrow, in an experimental rabbit model of osteomyelitis caused by carbapenemase-producing Enterobacterales.

International journal of antimicrobial agents·2023
Same author

Attitudes towards monkeypox vaccination among healthcare workers in France and Belgium: an element of complacency?

The Journal of hospital infection·2022
Same author

Heterologous prime boost COVID 19 vaccination.

Infectious diseases now·2022
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Beta-lactamase inhibitors combat bacterial resistance to penicillin and cephalosporins by inactivating key enzymes. Rational prescription is crucial to prevent further resistance and optimize treatment outcomes.

Area of Science:

  • Microbiology
  • Pharmacology

Context:

  • Bacterial resistance to beta-lactam antibiotics is a significant clinical challenge.
  • Beta-lactamase enzymes are a primary mechanism of this resistance.

Purpose:

  • To highlight the role of beta-lactamase inhibitors in overcoming bacterial resistance.
  • To discuss the clinical applications and limitations of these inhibitors.

Summary:

  • Beta-lactamase inhibitors (e.g., clavulanic acid, sulbactam, tazobactam) inactivate beta-lactamase enzymes, restoring the efficacy of beta-lactam antibiotics.
  • These combinations offer broad-spectrum bactericidal activity against various pathogens, including Gram-negative bacilli, anaerobes, and certain Gram-positive bacteria.
  • They are valuable in treating specific community-acquired and nosocomial infections.

Related Experiment Videos

Impact:

  • Widespread use necessitates judicious prescription to mitigate the selection of resistant strains.
  • Low toxicity and manageable side effects, primarily gastrointestinal, are dose-dependent.
  • Optimizing dosing and treatment duration, and de-escalating therapy when appropriate, are essential for effective and sustainable use.